Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 13Gastrointestinal 3Head & Neck 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × talimogene laherparepvec × Head & Neck × Clear all
NCT02626000 2021-09-08

MASTERKEY232

Amgen

Phase 1 Completed
36 enrolled 18 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01161498 2016-02-08

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

BioVex Limited

Phase 3 Terminated
5 enrolled 8 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡